2024-519537-29-00CompletedPhase 1
A Phase I Study of BMS-986497 alone or in combination with Azacitidine (Aza) and Azacitidine plus Venetoclax (AZA+VEN) in relapsed or refractory (R/R) AML or MDS
Source: EU CTIS (euclinicaltrials.eu) · Last updated 7 Aug 2026
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 35 (actual)
- First submitted
- 12 Jun 2025
- Start date
- 13 Mar 2026
- Lead sponsor
- Bristol-Myers Squibb Services Unlimited Company
- EU CT number
- 2024-519537-29-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 35
- 5 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (5)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Clinic de Barcelona | Barcelona | Spain | Completed |
| University Hospital Virgen Del Rocio S.L. | Sevilla | Spain | Completed |
| Institut Paoli-Calmettes | Marseille | France | Completed |
| Assistance Publique Hopitaux de Paris | Paris | France | Completed |
| Oncopole Claudius Regaud | Toulouse Cedex 9 | France | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.